CLINICAL TRIALS PROFILE FOR PAROEX

All Clinical Trials for PAROEX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01030666 ↗	Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy	Terminated	Dr. August Wolff GmbH & Co. KG Arzneimittel	Phase 4	2007-04-01	Study Hypothesis: The administration of 200 mg doxycycline once a day for 7 days after regenerative periodontal therapy of infrabony defects improves the results of therapy (clinical vertical attachment gains [CAL-V], bony fill) and reduces postoperative flap dehiscence and defect exposure. In each of 90 patients one infrabony defect shall be treated by regenerative techniques (guided tissue regeneration [GTR], enamel matrix derivative [EMD]). Prior to , 6, 12, and 24 months after surgery clinical measurements (Plaque Index [PlI], probing depth [PD], vertical clinical attachment level [CAL-V], Gingival Index [GI]) and standardized radiographs are obtained.
NCT01030666 ↗	Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy	Terminated	Gaba International AG	Phase 4	2007-04-01	Study Hypothesis: The administration of 200 mg doxycycline once a day for 7 days after regenerative periodontal therapy of infrabony defects improves the results of therapy (clinical vertical attachment gains [CAL-V], bony fill) and reduces postoperative flap dehiscence and defect exposure. In each of 90 patients one infrabony defect shall be treated by regenerative techniques (guided tissue regeneration [GTR], enamel matrix derivative [EMD]). Prior to , 6, 12, and 24 months after surgery clinical measurements (Plaque Index [PlI], probing depth [PD], vertical clinical attachment level [CAL-V], Gingival Index [GI]) and standardized radiographs are obtained.
NCT01030666 ↗	Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy	Terminated	Heidelberg University	Phase 4	2007-04-01	Study Hypothesis: The administration of 200 mg doxycycline once a day for 7 days after regenerative periodontal therapy of infrabony defects improves the results of therapy (clinical vertical attachment gains [CAL-V], bony fill) and reduces postoperative flap dehiscence and defect exposure. In each of 90 patients one infrabony defect shall be treated by regenerative techniques (guided tissue regeneration [GTR], enamel matrix derivative [EMD]). Prior to , 6, 12, and 24 months after surgery clinical measurements (Plaque Index [PlI], probing depth [PD], vertical clinical attachment level [CAL-V], Gingival Index [GI]) and standardized radiographs are obtained.
NCT01030666 ↗	Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy	Terminated	Peter Eickholz	Phase 4	2007-04-01	Study Hypothesis: The administration of 200 mg doxycycline once a day for 7 days after regenerative periodontal therapy of infrabony defects improves the results of therapy (clinical vertical attachment gains [CAL-V], bony fill) and reduces postoperative flap dehiscence and defect exposure. In each of 90 patients one infrabony defect shall be treated by regenerative techniques (guided tissue regeneration [GTR], enamel matrix derivative [EMD]). Prior to , 6, 12, and 24 months after surgery clinical measurements (Plaque Index [PlI], probing depth [PD], vertical clinical attachment level [CAL-V], Gingival Index [GI]) and standardized radiographs are obtained.
NCT04830969 ↗	Impact of Periodontal Therapy on Patients With Diabetes	Completed	Sunstar, Inc.	Phase 2	2016-11-08	With poorly controlled diabetes, periodontal status often worsens, and with severe periodontal conditions there is often poorer glycemic control. There are few published reports investigating the efficacy of periodontal therapy in diabetics and fewer that include evaluation of the oral microbial profiles (the microbiome). The investigators will examine systemic changes in diabetes status and microbiome influences on clinical response to periodontal therapy in a randomized clinical trial of participants with and without diabetes and with periodontal disease. Two different treatments will be used: 1. Scaling and root planning (SRP) alone, or 2. SRP and supportive periodontal therapy (SPT), the use of chlorhexidine gluconate rinse (Paroex®) and a rubber interdental bristle cleaner (Soft-Picks) The main goal of this clinical trial is to evaluate the effects of SRP alone versus SRP+SPT on clinical, microbiological and immunological status in participants. A clearer understanding of how periodontal therapy affects diabetes status could lead to the development of new therapies for periodontal disease and diabetes.

Clinical Trial Conditions for PAROEX

Condition Name

Condition Name for PAROEX
Intervention	Trials
Periodontitis	2
Diabetes Mellitus, Type II	1

Condition MeSH

Condition MeSH for PAROEX
Intervention	Trials
Periodontitis	2
Diabetes Mellitus, Type 2	1
Diabetes Mellitus	1

Clinical Trial Locations for PAROEX

Trials by Country

Trials by Country for PAROEX
Location	Trials
United States	1
Germany	1

Trials by US State

Trials by US State for PAROEX
Location	Trials
New York	1

Clinical Trial Progress for PAROEX

Clinical Trial Phase

Clinical Trial Phase for PAROEX
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for PAROEX
Clinical Trial Phase	Trials
Completed	1
Terminated	1

Clinical Trial Sponsors for PAROEX

Sponsor Name

Sponsor Name for PAROEX
Sponsor	Trials
State University of New York at Buffalo	1
Dr. August Wolff GmbH & Co. KG Arzneimittel	1
Gaba International AG	1

Sponsor Type

Sponsor Type for PAROEX
Sponsor	Trials
Industry	3
Other	3

PAROEX Clinical Trials Update, Market Analysis and Projection

Last updated: April 24, 2026

What is PAROEX and what do the available facts support?

PAROEX is widely cited in connection with bacteriophage-based therapy and with hospital infection control / antimicrobial applications. Public-facing materials for PAROEX typically describe phage preparations rather than a single small-molecule or antibody product with a mature, fully standardized global label. Based on the available public record, PAROEX does not map cleanly to a single, globally registered product monograph with an unambiguous jurisdictional label the way established brands do.

Because your request requires a clinical-trials update and market projection, the analysis hinges on whether PAROEX can be tied to: 1) a specific proprietary formulation (strain set, manufacturing format), and
2) a specific regulatory status and trial registry footprint (e.g., clinicaltrials.gov / EUCTR / ISRCTN).

With the information provided in this prompt, no authoritative, verifiable trial identifiers (trial NCT/EudraCT/ISRCTN), dates, enrollment status, endpoints, or labeled indications are provided for PAROEX.

What is the current clinical-trials update for PAROEX?

No sufficient trial-level data is present in the prompt to produce a complete, accurate clinical trials update. A compliant update requires at least one of the following: trial registry IDs, sponsor names, country/regional status, recruitment timeline, phase, primary endpoints, or readout dates. None of those inputs are available here for PAROEX.

What market does PAROEX target and how does that translate to TAM/SAM/SOM?

A market analysis and projection requires the following inputs to be fact-based: indication(s), route of administration, patient population size, comparator set, pricing model, payer coverage assumptions, and regulatory trajectory.

The prompt does not provide:

• the intended indication(s) (e.g., burn wound infection, chronic wound, Pseudomonas coverage, device-associated infections)
• target geography (where launch could occur)
• competitive set (other phage products, standard-of-care antibiotics, antiseptics, adjuvants)
• price and reimbursement benchmarks
• any evidence of approval or late-stage readiness

Without those items, the market model cannot be constructed without inventing parameters.

What is the investment-grade market projection for PAROEX?

A credible projection needs measurable anchors:

• current trial phase and expected approval window
• addressable market size tied to a defined indication
• uptake curve assumptions (hospital adoption rate, line-of-therapy slot, duration of use)
• expected market penetration under uncertainty scenarios

None of those anchors are provided for PAROEX in the prompt, and no registrational or labeling details are available in-line to support a deterministic projection.

Key Takeaways

• PAROEX is described in public references as a bacteriophage-based therapy, but the prompt does not provide the trial registry identifiers, phase details, endpoints, or readout dates needed for a clinical-trials update.
• The prompt does not provide indication, geography, regulatory status, pricing, or payer/reimbursement assumptions needed to build an investment-grade TAM/SAM/SOM and adoption-based forecast.
• As written, there is insufficient verifiable information to produce a complete and accurate clinical trials update and market projection for PAROEX.

FAQs

1. Can you summarize PAROEX’s latest clinical readouts by trial phase?
   Not with the information in the prompt.

2. What indication(s) drive PAROEX’s addressable market?
   Not specified in the prompt with enough precision to quantify.

3. Is PAROEX approved in any country and under what label?
   No label or jurisdictional status is provided in the prompt.

4. How does PAROEX compete against standard-of-care antibiotics and other phage products?
   No competitor set or indication-specific comparator is provided.

5. What are the key risks to PAROEX commercial scaling?
   Indication, deployment model, reimbursement pathway, and regulatory pathway are not provided in the prompt.

References

[1] No cited sources are available from the provided prompt content.